Plain-English translation of NCT05180773 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Peripartum cardiomyopathy is a serious heart condition that affects some women during pregnancy or within months after giving birth. This trial tests whether a medication called can help the heart recover better when combined with standard heart failure treatments. Half of the participants will receive the medication for 8 weeks, while the other half will receive a placebo (a pill with no active ingredient), and doctors will track how well each person's heart function improves over 12 months.
Doctors don't yet know the best way to treat peripartum cardiomyopathy to help women's hearts recover fully. Early research suggests this medication might help by lowering a hormone called prolactin, which may be involved in heart damage. This trial will determine whether adding this treatment to standard heart medications actually improves recovery.
You likely qualify if…
You likely don't qualify if…
You would visit the study center at the start, then again at 6 months and 12 months after enrollment for heart imaging tests (echocardiograms) to measure your heart's recovery. If you're assigned to the treatment group, you'll take the medication twice daily for 2 weeks, then once daily for 6 weeks, along with your regular heart medications and a blood thinner to prevent clots. You'll also be followed for up to 3 years total to track your long-term heart health and any major cardiac events.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States